EGFR突变晚期非小细胞肺癌以EGFR-TKIs为基础的治疗进展  

Research Progress of EGFR-TKIs in Treatment of EGFR-mutated Advanced Non-small Cell Lung Cancer

作　　者：刘正玲 李文君[1] 陶红艳[1] 万毅新[1] LIU Zhengling;LI Wenjun;TAO Hongyan;WAN Yixin(Department of Respiratory Medicine,Lanzhou University Second Hospital,Lanzhou 730030,China;Second Clinical Medical College of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第二医院呼吸内科,兰州730030 [2]兰州大学第二临床医学院,兰州730000

出　　处：《医学综述》2021年第22期4458-4464,共7页Medical Recapitulate

基　　金：甘肃省高等学校科学研究项目(2018B-014)。

摘　　要：肺癌是指原发于气管、支气管和肺的恶性肿瘤,分为非小细胞肺癌(NSCLC)和小细胞肺癌两种类型。早期NSCLC患者通常无症状,确诊时多为Ⅲ/Ⅳ期,错过最佳手术治疗时期。晚期NSCLC传统治疗方案是以铂类为基础的联合化疗,近年来,随着精准医疗的发展,分子靶向治疗已广泛应用于癌症领域,一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)逐渐代替化疗成为EGFR突变晚期NSCLC患者的标准治疗方案。尽管EGFR-TKIs可有效改善晚期NSCLC患者无进展生存期和客观缓解率,但仍不可避免地产生耐药,因此探索以EGFR-TKIs为基础的联合治疗具有重要的临床意义。Lung cancer is a malignant tumor that occurs primarily in the trachea,bronchus and lung,which is categorized into non-small cell lung cancer(NSCLC)and small cell lung cancer.Early NSCLC is usually asymptomatic,and is mostly at stageⅢ/Ⅳwhen diagnosed,missing the optimal time for surgical treatment.The traditional treatment for advanced NSCLC is platinum-based combined chemotherapy,while in recent years,with the development of precision medicine,molecular targeted therapy has been widely used in the field of cancer,and the first-line drugs of epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)treatment are gradually replacing chemotherapy and becoming the standard treatment of patients with advanced EGFR-mutated NSCLC.Although EGFR-TKIs have effectively improved progression-free survival and objective response rate in patients with advanced NSCLC,drug resistance is still inevitable,therefore,it is of great clinical significance to explore the combination therapy based on EGFR-TKIs.

关 键 词：晚期非小细胞肺癌 表皮生长因子受体突变 靶向治疗 表皮生长因子受体酪氨酸激酶抑制剂 化疗 

分 类 号：R563.9[医药卫生—呼吸系统]